Sophiris Bio, Inc. (NASDAQ:SPHS) received a $6.00 target price from stock analysts at Maxim Group in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would suggest a potential upside of 179.59% from the company’s current price.

The analysts wrote, “Sophiris announced that the last patient to be dosed with topsalysin (P2b study in men with localized prostate cancer -PC), should occur by month’s end.””

SPHS has been the subject of a number of other research reports. HC Wainwright set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Saturday, June 10th. ValuEngine lowered shares of Sophiris Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $6.60.

Sophiris Bio (NASDAQ:SPHS) traded up 2.5116% during trading on Monday, reaching $2.1999. 116,585 shares of the company were exchanged. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $3.30. The stock has a 50 day moving average price of $2.03 and a 200 day moving average price of $2.32. The firm’s market capitalization is $66.24 million.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/02/sophiris-bio-inc-sphs-earns-buy-rating-from-maxim-group.html.

An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. bought a new stake in Sophiris Bio, Inc. (NASDAQ:SPHS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned approximately 0.18% of Sophiris Bio as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.01% of the company’s stock.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.